View Alert


Originator: CMO Messaging

From: CMO Messaging

Issue date: 12-Feb-2021 14:19:08

This alert has been issued to:
  • NHS Regional Offices
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • NHS Trusts (England) - Medical Director
  • NHS Trusts (England) - Chief Executive

  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • Social Care Providers (registered with CAS)
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • Consultants in Communicable Diseases
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health
  • GP - Locum
  • NHS 111 and Out of hours providers
  • GP Practices
  • Out of hours contacts
  • Primary Care Networks

Action category: Important information for immediate action

Title: Colchicine in the Management of COVID-19 (SARS-CoV 2) Positive Patients - Trial Use Only

Broadcast content:

Colchicine should not be used in the management of COVID-19 positive patients other than in the context of a trial, or unless there is an additional licensed indication for its use.






Additional information: NHS England and NHS Improvement Regional Offices: please cascade this alert to Community Pharmacy

Alert reference: CEM/CMO/2021/005

Attachments:

Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency